Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runway [Yahoo! Finance]
Tenaya Therapeutics, Inc. (TNYA)
Company Research
Source: Yahoo! Finance
Tenaya Therapeutics (TNYA) recently completed a US$60 million capital raise, extending its cash runway into mid-2027. This is a key development for a company funding clinical-stage gene therapy programs for heart disease. See our latest analysis for Tenaya Therapeutics. Despite the fresh funding, Tenaya's recent share price performance has been weak, with a 90 day share price return showing a 56% decline and a 1 year total shareholder return showing a 39.64% decline, suggesting recent momentum has been fading. If this kind of volatility has you thinking about diversification, it could be worth scanning other healthcare stocks that might offer a different balance of risk and opportunity. With the shares around US$0.73 after a steep 90 day and 1 year decline, yet sitting below some analyst targets, you have to ask: is Tenaya quietly undervalued here, or is the market already discounting its future growth? Tenaya currently trades on a P/B of 1.9x, compared with 2.7x for both t
Show less
Read more
Impact Snapshot
Event Time:
TNYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNYA alerts
High impacting Tenaya Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNYA
News
- William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics, Inc. (TNYA) Reports Q4 EPS of (12c), In Line with Consensus [Yahoo! Finance]Yahoo! Finance
- Tenaya Therapeutics (TNYA) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TNYA&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hoMarketBeat
- Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
- Tenaya Therapeutics (TNYA) had its "outperform" rating reaffirmed by William Blair.MarketBeat
TNYA
Earnings
- 3/11/26 - Beat
TNYA
Sec Filings
- 3/11/26 - Form 10-K
- 3/11/26 - Form 8-K
- 3/5/26 - Form 8-K
- TNYA's page on the SEC website